Raytheon awarded $71 million in Navy contracts for missile systems
CONSHOHOCKEN, Pa. - On Wednesday, Cencora, Inc. (NYSE:COR) reported third-quarter fiscal 2025 results that exceeded analyst expectations, with adjusted earnings per share of $4.00 beating the consensus estimate of $3.84 and revenue of $80.7 billion surpassing the expected $80.31 billion.
Following the announcement, Cencora shares dipped slightly by 0.46% in pre-market trading.
The pharmaceutical solutions organization saw revenue increase 8.7% YoY, driven by its U.S. Healthcare Solutions segment, which grew 8.5%, and its International Healthcare Solutions segment, which increased 10.5%. Adjusted diluted earnings per share rose 19.8% from $3.34 in the prior year quarter.
"Cencora delivered strong financial results in the third fiscal quarter, driven by our pharmaceutical-centric strategy and focus on our growth priorities," said Robert P. Mauch, President and Chief Executive Officer of Cencora. "Our teams are fueling our growth as they identify opportunities and customer-centric solutions that strengthen our value proposition as the partner of choice."
The company raised its full-year adjusted earnings guidance to a range of $15.85 to $16.00 per share, up from its previous forecast of $15.70 to $15.95 and above the analyst consensus of $15.84. This increase primarily reflects stronger earnings growth in the U.S. Healthcare Solutions segment, where operating income jumped 29.1% in the quarter.
Cencora now expects consolidated revenue growth of approximately 9% for fiscal 2025, with U.S. Healthcare Solutions segment revenue growth of 9-10% and International Healthcare Solutions segment revenue growth of 6-7%.
The company’s Board of Directors declared a quarterly cash dividend of $0.55 per common share, payable September 3, 2025, to stockholders of record at the close of business on August 15, 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.